Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization

Journal of Molecular and Cellular Cardiology

Volumn 57, Issue 1, 2013, Pages 32-42

  Steinmetz, Martin ^a   Pelster, Bastian ^a   Lucanus, Eva ^a   Arnal, Jean Francois ^b   Nickenig, Georg ^a   Werner, Nikos ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b INSERM   (France)

Author keywords

Endothelium; Fibroblast growth factor 2; Progenitor cells; RANKL; Statins

Indexed keywords

ATAXIN 1; ATORVASTATIN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ELECTRIC INJURY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL MOBILIZATION;

ANIMALS; ANTIGENS, LY; BONE MARROW; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 2; HEPTANOIC ACIDS; HINDLIMB; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOPROTEGERIN; PERFUSION; PYRROLES; RANK LIGAND; RE-EPITHELIALIZATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 84873422737     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.12.018     Document Type: Article

References (49)

1. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
2. Zengin E., Chalajour F., Gehling U.M., Ito W.D., Treede H., Lauke H., et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006, 133:1543-1551.
3. Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002, 22:1567-1572.
4. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007.
5. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., Murayama T., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105:3017-3024.
6. Strehlow K., Werner N., Berweiler J., Link A., Dirnagl U., Priller J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107:3059-3065.
7. Cho H.J., Kim H.S., Lee M.M., Kim D.H., Yang H.J., Hur J., et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 2003, 108:2918-2925.
8. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
9. Aicher A., Kollet O., Heeschen C., Liebner S., Urbich C., Ihling C., et al. The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 2008, 103:796-803.
10. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
11. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885-2890.
12. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399-405.
13. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
14. Okada Y., Montero A., Zhang X., Sobue T., Lorenzo J., Doetschman T., et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J Biol Chem 2003, 278:21258-21266.
15. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203:325-330.
16. Edwards C.J., Spector T.D. Statins as modulators of bone formation. Arthritis Res 2002, 4:151-153.
17. Steinmetz M., Brouwers C., Nickenig G., Wassmann S. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. J Cell Mol Med 2008, 14:1645-1656.
18. Pitchford S.C., Furze R.C., Jones C.P., Wengner A.M., Rankin S.M. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009, 4:62-72.
19. Lindner V., Fingerle J., Reidy M.A. Mouse model of arterial injury. Circ Res 1993, 73:792-796.
20. Carmeliet P., Moons L., Stassen J.M., De Mol M., Bouche A., van den Oord J.J., et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997, 150:761-776.
21. Petoumenos V., Nickenig G., Werner N. High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med 2009, 13:4623-4635.
22. Smadja D.M., Bieche I., Silvestre J.S., Germain S., Cornet A., Laurendeau I., et al. Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler Thromb Vasc Biol 2008, 28:2137-2143.
23. Wassmann S., Stumpf M., Strehlow K., Schmid A., Schieffer B., Bohm M., et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004, 94:534-541.
24. Sundaram K., Senn J., Yuvaraj S., Rao D.S., Reddy S.V. FGF-2 stimulation of RANK ligand expression in Paget's disease of bone. Mol Endocrinol 2009, 23:1445-1454.
25. Roccisana J.L., Kawanabe N., Kajiya H., Koide M., Roodman G.D., Reddy S.V. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2004, 279:10500-10507.
26. Nakagawa N., Yasuda H., Yano K., Mochizuki S., Kobayashi N., Fujimoto H., et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Biochem Biophys Res Commun 1999, 265:158-163.
27. Pitchford S.C., Hahnel M.J., Jones C.P., Rankin S.M. Troubleshooting: Quantification of mobilization of progenitor cell subsets from bone marrow in vivo. J Pharmacol Toxicol Methods 2010, 61:113-121.
28. Kinlay S., Libby P., Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001, 12:383-389.
29. Antoniades C., Bakogiannis C., Leeson P., Guzik T.J., Zhang M.H., Tousoulis D., et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011, 124:335-345.
30. Puccetti L., Santilli F., Pasqui A.L., Lattanzio S., Liani R., Ciani F., et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011, 214:122-128.
31. Puato M., Faggin E., Rattazzi M., Zambon A., Cipollone F., Grego F., et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke 2010, 41:1163-1168.
32. Houssen M.E., Haron M.M., Metwally S.S., Ibrahim T.M. Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis. J Physiol Biochem 2011, 67:115-120.
33. Spyridopoulos I., Haendeler J., Urbich C., Brummendorf T.H., Oh H., Schneider M.D., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004, 110:3136-3142.
34. - progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med 2010, 267:385-393.
35. Chikazu D., Katagiri M., Ogasawara T., Ogata N., Shimoaka T., Takato T., et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res 2001, 16:2074-2081.
36. Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008, 473:139-146.
37. Byon C.H., Sun Y., Chen J., Yuan K., Mao X., Heath J.M., et al. Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011, 31:1387-1396.
38. Steinmetz M., Skowasch D., Wernert N., Welsch U., Preusse C.J., Welz A., et al. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008, 17:187-193.
39. Ovchinnikova O., Gylfe A., Bailey L., Nordstrom A., Rudling M., Jung C., et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol 2009, 29:1478-1480.
40. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
41. Foteinos G., Hu Y., Xiao Q., Metzler B., Xu Q. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation 2008, 117:1856-1863.
42. Zimmer S., Steinmetz M., Asdonk T., Motz I., Coch C., Hartmann E., et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res 2011, 108:1358-1366.
43. Assmus B., Urbich C., Aicher A., Hofmann W.K., Haendeler J., Rossig L., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049-1055.
44. Gossl M., Modder U.I., Gulati R., Rihal C.S., Prasad A., Loeffler D., et al. Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J 2010, 31:2909-2914.
45. McGonigle J.S., Giachelli C.M., Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009, 12:35-46.
46. Min J.K., Cho Y.L., Choi J.H., Kim Y., Kim J.H., Yu Y.S., et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007, 109:1495-1502.
47. Moon H.J., Kim S.E., Yun Y.P., Hwang Y.S., Bang J.B., Park J.H., et al. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med 2011, 43:605-612.
48. Kaji H., Kanatani M., Sugimoto T., Chihara K. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 2005, 37:589-592.
49. Shiota M., Hikita Y., Kawamoto Y., Kusakabe H., Tanaka M., Izumi Y., et al. Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. J Cell Mol Med 2012, 6:2001-2009.